1. J. M. Howard, M. J. Collen, J. A. Cherner, K. A. McArthur, P. N. Maton and J. D. Gardner,Famotidine: an effective, potent H2 antagonist for the therapy of Zollinger-Ellison syndrome. Gastroenterology86, 1117 (1984).
2. D. J. Hetzel, D. J. C. Shearman, M. G. Korman, J. Hansky, D. Piper and K. Ellard,Famotidine (MK 208) in the treatment of duodenal ulcer (DU). Short term multicentre studies and maintenance trial. Aust. N. Z. J. Med.15, Suppl. 2, 547 (1985).
3. J. Lacey-Smith, M. A. Gamal, A. N. Chremos and D. Y. Graham,Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal and pepsin secretion in man. Dig. Dis. Sci.30, 308–312 (1985).
4. B. Simon, H. G. Damman, G. Jakob, S. E. Miederer, P. Mueller, R. Ottenjann, P. F. Scholten, T. H. Schutz, E. Seifert and O. Stadelmann,Famotidine versus ranitidine in the short term treatment of duodenal ulcer—a double blind randomized multicenter study in Germany. Z. Gastroenterol.23, 47–51 (1985).
5. J. P. Buyniski, R. L. Cavanagh, A. W. Pircio, A. A. Algieri and R. R. Crenshaw, Structure-activity relationships among newer histamine H2-receptor antagonists, InHighlights in receptor chemistry, p. 195 (Eds. C. Melchiorre and M. Giannella). Elsevier, Amsterdam 1984.